Publication:
The effect of at least 1-year use of omalizumab without interruption on relapse in patients with chronic spontaneous urticaria

Simple item page
dc.contributor.authorSu, Ozlem
dc.contributor.authorBAHALI, ANIL GÜLSEL
dc.contributor.authorONSUN, Nahide
dc.contributor.institutionauthorSU KÜÇÜK, ÖZLEM
dc.contributor.institutionauthorBAHALI, ANIL GÜLSEL
dc.contributor.institutionauthorONSUN, NAHIDE
dc.date.accessioned2020-10-22T20:23:42Z
dc.date.available2020-10-22T20:23:42Z
dc.date.issued2020-09-01T00:00:00Z
dc.description.abstractIt is known that omalizumab (OMA) is an effective and safe treatment option in the treatment of chronic spontaneous urticaria (CSU). In the literature, there are vary studies about effect of OMA treatment in CSU such as different response rates to treatment, different dose / time regime and different relapse rates after treatment. To investigate the evaluate the effect of at least 1 year continuous OMA treatment on relapse in CSU patients. Fifty patients were included in this study. There was a significant decreased between UAS7 score before and after OMA treatment. There was no significant difference between the sixth and 12th month after OMA for UAS 7 scores. At the end of 12 month,84% of patients had complete or good response to OMA treatment. Twenty-three of 34 patients (67.6%) who discontinued treatment had relapse and 11 patients had no relapse. Duration of disease was significantly higher in patients who had relapse. Based on our study result we suggest that long disease duration may increase the risk of relapse. Although it is not statistically significant, without interruption OMA treatment for more than 1 year may decrease relapse risk in patients who respond well to the therapy.
dc.identifier.citationSu O., BAHALI A. G. , ONSUN N., -The effect of at least 1-year use of omalizumab without interruption on relapse in patients with chronic spontaneous urticaria-, DERMATOLOGIC THERAPY, 2020
dc.identifier.doi10.1111/dth.14192
dc.identifier.pubmed32790183
dc.identifier.scopus85090308719
dc.identifier.urihttp://hdl.handle.net/20.500.12645/24754
dc.identifier.wosWOS:000566811800001
dc.titleThe effect of at least 1-year use of omalizumab without interruption on relapse in patients with chronic spontaneous urticaria
dc.typeArticle
dspace.entity.typePublication
local.avesis.ide379052f-a890-4437-a8f8-c4791ea3d464
local.publication.isinternational1
relation.isAuthorOfPublicationfd8dc121-9bbe-4ee4-a2fd-5e237676169d
relation.isAuthorOfPublication707cb0db-18b7-40e0-be43-9081b2711b89
relation.isAuthorOfPublication1ebc9a95-ecf2-4c81-9f74-3c5fb32a9406
relation.isAuthorOfPublication.latestForDiscovery707cb0db-18b7-40e0-be43-9081b2711b89
Files
Collections
Yayınlar - Eserler